1887

Abstract

Ribavirin (RBV) has been used for the last 20 years to treat patients with chronic hepatitis C virus (HCV) infection. This pluripotent drug is believed to induce mutagenesis in HCV RNA. However, for cell-cultured HCV (HCVcc) this phenomenon has only been investigated in genotype 2a recombinants. Here we studied the mutations that developed in HCVcc of genotypes 1a and 3a treated with RBV or ribavirin triphosphate (RBV-TP) compared to non-treated controls. Analysis was performed on the amplified full-length open reading frame (ORF) of recovered viruses following next-generation sequencing and clonal analyses. Compared to non-treated controls, the spread of TNcc(1a) and DBN3acc(3a) HCVcc was delayed by RBV and RBV-TP at concentrations of 40 µM or higher. The delay in HCVcc spread was associated with increased new single-nucleotide polymorphisms (SNP). Significantly higher numbers of new SNP were observed in TNcc(1a) viruses treated with RBV or RBV-TP compared to matched non-treated controls. RBV or RBV-TP treatment led to significantly increased proportions of new G-to-A and C-to-U SNP compared to non-treated TNcc(1a). Clonal analyses confirmed a significantly increased mutation rate in RBV-treated TNcc(1a). Synonymous pairwise distances increased in both viruses across the complete ORF under RBV and RBV-TP treatment compared to controls. Consensus-shifts in single samples of RBV- or RBV-TP-treated TNcc(1a) viruses occurred in proteins E1, p7, NS3 and NS4B. No non-synonymous consensus changes were observed in DBN3acc(3a). This study supports a biased G-to-A and C-to-U mutagenic effect of RBV and RBV-TP throughout the entire ORF of HCV genotypes 1a and 3a.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001095
2018-06-21
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/8/1066.html?itemId=/content/journal/jgv/10.1099/jgv.0.001095&mimeType=html&fmt=ahah

References

  1. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet 1998;352:1426–1432[PubMed]
    [Google Scholar]
  2. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med 1998;339:1485–1492 [CrossRef][PubMed]
    [Google Scholar]
  3. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet 1998;351:83–87 [CrossRef][PubMed]
    [Google Scholar]
  4. Dusheiko G, Main J, Thomas H, Reichard O, Lee C et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591–598 [CrossRef][PubMed]
    [Google Scholar]
  5. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F et al. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017;37:5–18 [CrossRef][PubMed]
    [Google Scholar]
  6. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703–714 [CrossRef][PubMed]
    [Google Scholar]
  7. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967–972 [CrossRef][PubMed]
    [Google Scholar]
  8. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62:S87–S99 [CrossRef][PubMed]
    [Google Scholar]
  9. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB et al. Oral direct-acting agent therapy for hepatitis C Virus infection: a systematic review. Ann Intern Med 2017;166:637–648 [CrossRef][PubMed]
    [Google Scholar]
  10. Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C et al. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir Ther 2007;12:805–813[PubMed]
    [Google Scholar]
  11. Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J. Antiviral effect of ribavirin against HCV associated with increased frequency of G-to-A and C-to-U transitions in infectious cell culture model. Sci Rep 2018;8:4619 [CrossRef][PubMed]
    [Google Scholar]
  12. Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J et al. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One 2013;8:e71039 [CrossRef][PubMed]
    [Google Scholar]
  13. Feigelstock DA, Mihalik KB, Feinstone SM. Selection of hepatitis C virus resistant to ribavirin. Virol J 2011;8:402 [CrossRef][PubMed]
    [Google Scholar]
  14. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM et al. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci USA 2012;109:19757–19762 [CrossRef][PubMed]
    [Google Scholar]
  15. Bukh J. The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol 2016;65:S2–S21 [CrossRef][PubMed]
    [Google Scholar]
  16. Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J. Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir. Gastroenterology 2016;151:973–985 [CrossRef][PubMed]
    [Google Scholar]
  17. Waldenström J, Lagging M. Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis. Aliment Pharmacol Ther 2017;46:1115–1116 [CrossRef][PubMed]
    [Google Scholar]
  18. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L et al. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci USA 2012;109:E1101E1110 [CrossRef][PubMed]
    [Google Scholar]
  19. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005;43:623–629 [CrossRef][PubMed]
    [Google Scholar]
  20. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132:1757–1766 [CrossRef][PubMed]
    [Google Scholar]
  21. Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007;132:921–930 [CrossRef][PubMed]
    [Google Scholar]
  22. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 2005;79:2346–2355 [CrossRef][PubMed]
    [Google Scholar]
  23. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003;38:869–878 [CrossRef][PubMed]
    [Google Scholar]
  24. Airaksinen A, Pariente N, Menéndez-Arias L, Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003;311:339–349 [CrossRef][PubMed]
    [Google Scholar]
  25. Arias A, Isabel de Ávila A, Sanz-Ramos M, Agudo R, Escarmís C et al. Molecular dissection of a viral quasispecies under mutagenic treatment: positive correlation between fitness loss and mutational load. J Gen Virol 2013;94:817–830 [CrossRef][PubMed]
    [Google Scholar]
  26. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375–1379 [CrossRef][PubMed]
    [Google Scholar]
  27. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW et al. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 2005;67:38–45 [CrossRef][PubMed]
    [Google Scholar]
  28. Kim Y, Lee C. Ribavirin efficiently suppresses porcine nidovirus replication. Virus Res 2013;171:44–53 [CrossRef][PubMed]
    [Google Scholar]
  29. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001;75:8074–8081 [CrossRef][PubMed]
    [Google Scholar]
  30. Leyssen P, de Clercq E, Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol 2006;69:1461–1467 [CrossRef][PubMed]
    [Google Scholar]
  31. Moreno H, Gallego I, Sevilla N, de La Torre JC, Domingo E et al. Ribavirin can be mutagenic for arenaviruses. J Virol 2011;85:7246–7255 [CrossRef][PubMed]
    [Google Scholar]
  32. Perales C, Agudo R, Domingo E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 2009;4:e5554 [CrossRef][PubMed]
    [Google Scholar]
  33. Ruiz-Jarabo CM, Ly C, Domingo E, de La Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003;308:37–47 [CrossRef][PubMed]
    [Google Scholar]
  34. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003;77:481–488 [CrossRef][PubMed]
    [Google Scholar]
  35. Cheney IW, Naim S, Lai VC, Dempsey S, Bellows D et al. Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology 2002;297:298–306 [CrossRef][PubMed]
    [Google Scholar]
  36. Sheldon J, Beach NM, Moreno E, Gallego I, Piñeiro D et al. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol 2014;88:12098–12111 [CrossRef][PubMed]
    [Google Scholar]
  37. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002;76:8505–8517 [CrossRef][PubMed]
    [Google Scholar]
  38. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y et al. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004;11:479–487 [CrossRef][PubMed]
    [Google Scholar]
  39. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003;310:333–342 [CrossRef][PubMed]
    [Google Scholar]
  40. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276:46094–46098 [CrossRef][PubMed]
    [Google Scholar]
  41. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002;76:13001–13014 [CrossRef][PubMed]
    [Google Scholar]
  42. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007;133:1614–1626 [CrossRef][PubMed]
    [Google Scholar]
  43. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623–626 [CrossRef][PubMed]
    [Google Scholar]
  44. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010;84:5277–5293 [CrossRef][PubMed]
    [Google Scholar]
  45. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009;49:364–377 [CrossRef][PubMed]
    [Google Scholar]
  46. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011;140:1032–1042 [CrossRef][PubMed]
    [Google Scholar]
  47. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011;141:1067–1079 [CrossRef][PubMed]
    [Google Scholar]
  48. Fahnøe U, Pedersen AG, Dräger C, Orton RJ, Blome S et al. Creation of functional viruses from non-functional cDNA clones obtained from an RNA virus population by the use of ancestral reconstruction. PLoS One 2015;10:e0140912 [CrossRef][PubMed]
    [Google Scholar]
  49. Nelson CW, Moncla LH, Hughes AL. SNPGenie: estimating evolutionary parameters to detect natural selection using pooled next-generation sequencing data. Bioinformatics 2015;31:3709–3711 [CrossRef][PubMed]
    [Google Scholar]
  50. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016;33:1870–1874 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001095
Loading
/content/journal/jgv/10.1099/jgv.0.001095
Loading

Data & Media loading...

Supplementary File 1

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error